中段房钠尿肽前体改善缺血性卒中风险分层
这项前瞻性多中心队列研究在788例缺血性卒中发病24小时内检测MR-proANP,发现其与90天死亡独立相关(aHR 6.12),加入模型可提升死亡预测区分度(cNRI 49%);MR-proANP还与心源性卒中病因及房颤诊断相关,但对功能预后区分无显著改善。
要点
- MR-proANP与90天死亡独立相关,加入模型可改善死亡风险分层。
- MR-proANP对功能预后(mRS>2)的区分与重分类无显著改善。
- MR-proANP≥289 pmol/L诊断房颤特异性86%、敏感性48%。
核心结论
- MR-proANP是经新验证的血液生物标志物,可为卒中后死亡提供额外预后信息。
- 较高MR-proANP水平与心源性卒中病因相关,与房颤诊断的相关性更强。
研究设计与样本
- 前瞻性多中心队列研究,纳入788例缺血性卒中患者,在发病24小时内定量MR-proANP。
- 783例完成90天随访,118例(15%)死亡。
主要发现
- 充分校正后,MR-proANP与90天死亡相关(aHR 6.12,95%CI 2.36-15.84,p=0.01)。
- MR-proANP与功能预后相关(aOR 2.46,95%CI 1.05-5.74,p=0.038)。
- 死亡预测中加入MR-proANP提升区分度,cNRI为49%(95%CI 26%-78%,p<0.001)。
- 功能预后的区分度或重分类无显著改善。
- 心源性卒中病因与MR-proANP相关(aOR 2.10,95%CI 1.11-3.97,p=0.02),出院诊断房颤与之相关(aOR 18.35,95%CI 7.94-42.45,p<0.001)。
关键数值与推荐
- MR-proANP对心源性卒中病因的cNRI不显著;对房颤的cNRI为78%(95%CI 60%-89%,p<0.001)。
- MR-proANP≥289 pmol/L诊断房颤的特异性86%、敏感性48%。
临床怎么用
- 可考虑将MR-proANP用于缺血性卒中后死亡风险分层,辅助识别高危患者。
- MR-proANP升高提示心源性病因及房颤可能,可辅助病因评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To validate midregional proatrial natriuretic peptide (MR-proANP) for outcome prediction and diagnosis of cardioembolic stroke etiology compared to established clinical variables. METHODS: In this prospective multicenter cohort study, we quantified MR-proANP levels in ischemic stroke patients within 24 hours of onset. Primary outcome measures were 90-day mortality, unfavorable functional outcome (modified Rankin Scale score >2), and cardioembolic stroke etiology diagnosed during hospitalization. RESULTS: Of 788 included patients, 783 completed their 90-day follow-up, and 118 patients (15%) died. After full adjustment, MR-proANP levels were associated with 90-day mortality (adjusted hazard ratio 6.12, 95% confidence interval [CI] 2.36-15.84, p = 0.01) and functional outcome (adjusted odds ratio [aOR] 2.46, 95% CI 1.05-5.74, p = 0.038). For mortality prediction, adding MR-proANP to the regression model increased its discriminatory accuracy, and the continuous net reclassification index (cNRI) was 49% (95% CI 26%-78%, p < 0.001). For functional outcome, there was no significant improvement in discrimination or reclassification. Cardioembolic stroke etiology and the diagnosis of atrial fibrillation at hospital discharge were associated with MR-proANP with an aOR of 2.10 (95% CI 1.11-3.97, p = 0.02) and 18.35 (95% CI 7.94-42.45, p < 0.001), respectively. The cNRI of MR-proANP for cardioembolic stroke etiology was not significant, as opposed to atrial fibrillation (78%, 95% CI 60%-89%, p < 0.001). MR-proANP levels ≥289 pmol/L had a specificity of 86% and sensitivity of 48% for the diagnosis of atrial fibrillation. CONCLUSION: MR-proANP is a newly validated blood biomarker providing additional prognostic information for mortality after stroke. Higher MR-proANP levels were associated with cardioembolic stroke etiology and, even more strongly, atrial fibrillation.
引用
- De Marchis GM, Schneider J, Weck A, et al. Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke. Neurology. 2018. PMID: 29321236. doi:10.1212/WNL.0000000000004922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。